BAO PHARMA-B (02659) Shares Rise Nearly 6% as Chairman Liu Yanjun Increases Stake; IND Application for BJ045 Injection Approved

Stock News10-28

BAO PHARMA-B (02659) rose nearly 6% during intraday trading, up 3.16% as of press time to HK$8.15, with a turnover of HK$2.9609 million.

On the news front, the latest data from the Hong Kong Stock Exchange shows that on October 23, Chairman of the Board Liu Yanjun increased his holdings of BAO PHARMA-B by 102,100 shares at HK$7.4358 per share, for a total amount of approximately HK$759,200. After the increase, his latest shareholding stands at approximately 26.309 million shares, representing a latest shareholding ratio of 17.05%.

Recently, BAO PHARMA-B announced that the clinical trial application (IND) for its self-developed BJ045 injection (a subcutaneously administered anti-enzymatic degradation anti-CD20 monoclonal antibody, collectively referred to as BJ045) has been approved by the National Medical Products Administration of the People's Republic of China, granting permission to conduct clinical trials in China.

BJ045 is a subcutaneously administered anti-CD20 antibody that is resistant to IgG-degrading enzyme degradation, and possesses the potential to be used in combination with IgG-degrading enzymes (such as the company's KJ103) for the treatment of moderate-to-severe autoimmune diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment